Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Strategic partner Orchestra BioMed reported that the collaborative BACKBEAT pivotal trial, being conducted with Medtronic, is on track to reach its target of 284 evaluable randomized patients by the end of Q3 2026. The AVIM Therapy program secured a second FDA Breakthrough Device Designation, expanding the regulatory and reimbursement potential for the hypertension treatment co-developed with Medtronic.
Key figures
- Obio q2 revenue usd
- 88000
- Obio q2 net loss usd
- 24100000
- Obio cash balance usd
- 110000000
- Backbeat target patients
- 284
- Mdt total investment usd
- 82000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.